Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BCT 1702 (CHARIOT): A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab.

Trial Profile

BCT 1702 (CHARIOT): A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms CHARIOT
  • Most Recent Events

    • 12 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 25 May 2018 Planned End Date changed from 30 Apr 2022 to 30 Jun 2022.
    • 25 May 2018 Planned initiation date changed from 30 Apr 2018 to 30 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top